The Ginkgo biloba metabolite bilobalide is widely ingested by humans but its effect on the mammalian central nervous system is not fully understood 1,2,3,4. Antagonism of gammaaminobutyric acid A receptors (GABA A Rs) by bilobalide has been tied to rescue of cognitive deficits in mouse models of Down syndrome 5. A lack of convulsant activity coupled with these neuroprotective effects have led some to postulate an alternative, unidentified target. 4 However, steric congestion and the instability of 1 1,2,6 have prevented pulldown of biological targets other than the GABA A Rs. A concise and flexible synthesis of 1 would provide a platform to generate probes for identification of potential new targets; analogs with differential selectivity between insect and human GABA A Rs; and stabilized analogs with enhanced serum half-life 7. Here we exploit the unusual reactivity of bilobalide to affect a late-stage oxidation that symmetrizes the molecular core and allows oxidation states to be embedded in the starting material. The same overall strategy disclosed here may be applicable to G. biloba congeners including the ginkgolides, some of which are glycine receptor (GlyR)-selective antagonists 8. The therapeutic potential of bilobalide and its incompletely understood effects can now be interrogated through chemical synthesis.